Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target Increased to $52.00 by Analysts at SVB Leerink

Mirum Pharmaceuticals (NASDAQ:MIRMGet Rating) had its price target boosted by stock analysts at SVB Leerink from $50.00 to $52.00 in a research note issued on Tuesday, Stock Target Advisor reports. The firm currently has an “outperform” rating on the stock. SVB Leerink’s target price would suggest a potential upside of 106.10% from the company’s previous close.

Several other research firms have also recently issued reports on MIRM. Zacks Investment Research cut shares of Mirum Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, May 18th. Raymond James upped their price target on shares of Mirum Pharmaceuticals from $70.00 to $74.00 and gave the company a “strong-buy” rating in a report on Friday, March 11th. Finally, HC Wainwright upped their price target on shares of Mirum Pharmaceuticals from $64.00 to $69.00 and gave the company a “buy” rating in a report on Monday. One analyst has rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Mirum Pharmaceuticals presently has an average rating of “Buy” and an average price target of $47.67.

Shares of MIRM stock opened at $25.23 on Tuesday. The company has a market capitalization of $803.20 million, a PE ratio of -11.16 and a beta of 1.23. The firm has a fifty day simple moving average of $24.33 and a 200-day simple moving average of $20.06. Mirum Pharmaceuticals has a twelve month low of $12.82 and a twelve month high of $28.65.

Mirum Pharmaceuticals (NASDAQ:MIRMGet Rating) last announced its earnings results on Thursday, May 5th. The company reported ($1.17) earnings per share for the quarter, beating the consensus estimate of ($1.39) by $0.22. Mirum Pharmaceuticals had a negative net margin of 218.74% and a negative return on equity of 163.01%. During the same period in the prior year, the firm earned ($1.68) earnings per share. As a group, research analysts forecast that Mirum Pharmaceuticals will post -4.43 EPS for the current fiscal year.

Several large investors have recently modified their holdings of MIRM. Citigroup Inc. grew its position in shares of Mirum Pharmaceuticals by 348.7% during the fourth quarter. Citigroup Inc. now owns 1,844 shares of the company’s stock worth $29,000 after acquiring an additional 1,433 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of Mirum Pharmaceuticals during the first quarter worth about $41,000. Cubist Systematic Strategies LLC grew its position in shares of Mirum Pharmaceuticals by 223.9% during the third quarter. Cubist Systematic Strategies LLC now owns 5,240 shares of the company’s stock worth $104,000 after acquiring an additional 3,622 shares during the last quarter. Bank of America Corp DE grew its position in shares of Mirum Pharmaceuticals by 102.3% during the fourth quarter. Bank of America Corp DE now owns 6,706 shares of the company’s stock worth $107,000 after acquiring an additional 3,391 shares during the last quarter. Finally, Congress Wealth Management LLC DE bought a new position in shares of Mirum Pharmaceuticals during the fourth quarter worth about $160,000. 87.68% of the stock is currently owned by institutional investors.

About Mirum Pharmaceuticals (Get Rating)

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease.

Further Reading

Stock Target Advisor logo

Analyst Recommendations for Mirum Pharmaceuticals (NASDAQ:MIRM)

Receive News & Ratings for Mirum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.